Loading stock data...

Parnax Lab Limited

BSE: PARNAXLAB

BSE
131.65 1.65 (1.27%)

Prev Close

130

Open Price

131

Volume

4,012

Today Low / High

130 / 133

52 WK Low / High

81 / 145

Range

125 - 138

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 131.65, reflecting a change of 1.65 (1.26923%). The expected target range on the BSE is 125 - 138. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.

25 Feb 131.00 0.50%
24 Feb 130.00 0.00%
23 Feb 133.85 -3.06%
20 Feb 119.05 11.72%
19 Feb 123.05 -0.28%
18 Feb 124.00 -0.77%
17 Feb 128.00 -0.66%
16 Feb 117.95 7.08%
13 Feb 118.00 -0.04%
12 Feb 118.50 5.91%
11 Feb 118.20 0.25%
10 Feb 123.80 -1.33%
09 Feb 121.00 2.31%
06 Feb 118.00 0.85%
05 Feb 120.25 -0.42%
04 Feb 129.95 -4.85%
03 Feb 126.55 -3.44%
02 Feb 122.95 2.97%
01 Feb 120.00 2.71%
30 Jan 119.90 1.25%
29 Jan 116.95 -0.90%
28 Jan 114.00 -1.75%

Parnax Lab Limited Graph

Parnax Lab Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Parnax Lab Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 131.65, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 131.65 132.97 119.67 - 146.26
134.28 107.43 - 161.14
135.60 94.92 - 176.28
Bearish Scenario 131.65 130.33 117.30 - 143.37
129.02 103.21 - 154.82
127.70 89.39 - 166.01

Overview of Parnax Lab Limited

ISIN

INE383L01019

Industry

Medical - Pharmaceuticals

Vol.Avg

6,462

Market Cap

1,512,081,346

Last Dividend

0

Official Website

Visit Website

IPO Date

2024-12-30

DCF Diff

233.72

DCF

-107

Financial Ratios Every Investor Needs

Stock Rating Details for PARNAXLAB

Metric Value Recommendation
Overall Rating C- Strong Sell
DCF Score 1 Strong Sell
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 3 Neutral
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 187.74 Cr 96.00 Cr 91.74 Cr 0.4886 0.00 Cr 24.87 Cr 19.39 Cr 11.52 Cr 10.09 28.44 Cr 0.0614
2024-03-31 188.71 Cr 163.97 Cr 24.74 Cr 0.1311 0.58 Cr 4.83 Cr 16.68 Cr 9.61 Cr 8.37 24.36 Cr 0.0509
2023-03-31 167.61 Cr 116.34 Cr 51.27 Cr 0.3059 0.21 Cr 4.56 Cr 16.75 Cr 8.62 Cr 7.79 23.71 Cr 0.0514
2022-03-31 163.03 Cr 115.02 Cr 48.02 Cr 0.2945 0.28 Cr 4.16 Cr 17.63 Cr 8.24 Cr 9.68 23.30 Cr 0.0506
2021-03-31 90.06 Cr 60.51 Cr 29.55 Cr 0.3281 0.04 Cr 3.63 Cr 4.99 Cr -0.36 Cr -0.43 10.06 Cr -0.0040

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 0.55 Cr 189.82 Cr 106.58 Cr 83.0992 Cr 69.53 Cr 68.98 Cr 25.77 Cr 109.44 Cr 0.00 Cr 0.00 Cr 0.16 Cr 74.3339 Cr
2024-03-31 0.46 Cr 188.77 Cr 117.07 Cr 71.5727 Cr 80.64 Cr 80.18 Cr 29.93 Cr 111.70 Cr 0.06 Cr 0.00 Cr -0.58 Cr 81.8312 Cr
2023-03-31 1.28 Cr 145.07 Cr 82.81 Cr 62.1541 Cr 54.72 Cr 53.44 Cr 21.69 Cr 83.03 Cr 0.35 Cr 0.00 Cr 0.16 Cr 63.0417 Cr
2022-03-31 4.36 Cr 153.46 Cr 105.19 Cr 48.1864 Cr 69.07 Cr 64.71 Cr 19.93 Cr 75.20 Cr 0.00 Cr 0.00 Cr 0.22 Cr 80.9772 Cr
2021-03-31 0.18 Cr 106.26 Cr 73.64 Cr 32.5437 Cr 58.90 Cr 58.72 Cr 10.79 Cr 64.43 Cr 0.10 Cr 0.00 Cr 0.22 Cr 54.3740 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 32.3015 Cr -16.3941 Cr -15.8153 Cr 13.7235 Cr 0.0921 Cr 0.5499 Cr -18.5780 Cr 15.6742 Cr -10.4246 Cr 0.0000 Cr 4.1584 Cr
2024-03-31 15.8770 Cr -31.5159 Cr 14.8172 Cr -16.5380 Cr -0.8217 Cr 0.4578 Cr -32.4150 Cr 9.6092 Cr 20.1629 Cr 0.0000 Cr -8.2407 Cr
2023-03-31 20.9101 Cr -9.9240 Cr -14.0687 Cr 9.6298 Cr -3.0826 Cr 1.2795 Cr -11.2803 Cr 12.2797 Cr -14.5686 Cr 0.0000 Cr -1.7585 Cr
2022-03-31 8.5458 Cr -16.4989 Cr 12.1338 Cr -9.2821 Cr 4.1807 Cr 4.3621 Cr -17.8279 Cr 12.2642 Cr 9.8486 Cr 0.0000 Cr -9.1392 Cr
2021-03-31 6.3089 Cr -6.5649 Cr 0.0506 Cr -0.2312 Cr -0.2054 Cr 0.1814 Cr -6.5401 Cr -0.0837 Cr 5.1316 Cr 0.0000 Cr 0.3619 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-12-31 62.94 Cr 46.40 Cr 16.54 Cr 0.2629 4.89 Cr 2.71 Cr 2.36 6.85 Cr 0.0431
2025-09-30 62.60 Cr 44.86 Cr 17.74 Cr 0.2833 5.98 Cr 3.63 Cr 3.15 8.71 Cr 0.0580
2025-06-30 53.38 Cr 29.98 Cr 23.39 Cr 0.4383 5.49 Cr 3.27 Cr 2.85 7.62 Cr 0.0612
2025-03-31 49.04 Cr 26.28 Cr 22.76 Cr 0.4641 4.80 Cr 2.92 Cr 2.56 7.06 Cr 0.0595
2024-12-31 40.22 Cr 21.56 Cr 18.65 Cr 0.4638 2.49 Cr 1.21 Cr 1.06 4.46 Cr 0.0301

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-09-30 2.05 Cr 0.00 Cr 2.05 Cr 31.75 Cr 33.23 Cr 77.38 Cr 125.84 Cr 208.50 Cr 118.36 Cr
2025-06-30 0.00 Cr 0.00 Cr 2.68 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -83.24 Cr
2025-03-31 0.55 Cr 2.13 Cr 2.68 Cr 30.96 Cr 25.77 Cr 68.34 Cr 109.44 Cr 189.82 Cr 106.58 Cr
2024-12-31 0.00 Cr 0.00 Cr 1.68 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -79.10 Cr
2024-09-30 0.18 Cr 1.50 Cr 1.68 Cr 30.53 Cr 21.63 Cr 61.88 Cr 105.54 Cr 180.26 Cr 101.16 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-06-30 3.27 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2025-03-31 2.92 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 1.21 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 3.41 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 3.98 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹854.80 ₹102,578,890,079.00 ₹242,213.00

Key Executives

CFO & Director
Binoy Baiju Shah

Gender: male

Year Born: 1984

MD & Chief Executive Officer
Mihir Prakash Shah

Gender: male

Year Born:

Company Secretary & Compliance Officer
Preet Vijay Kukreja

Gender: female

Year Born:

FAQs about Parnax Lab Limited

Who is the CEO of the company?

The CEO is Mihir Prakash Shah.

What is the current market price of the stock?

The current price is ₹131.65.

What is the 52-week price range?

The range is ₹81-145.

What is the market capitalization of the company?

The market capitalization is ₹151.21 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 12.07.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Parnax Lab Limited (ISIN: INE383L01019) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹151.21 crores and an average daily volume of 6,462 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.